MDT
87.86
-1.21%↓
VEEV
221.66
-2.12%↓
A
109.71
-5.41%↓
HQY
82.88
-6.59%↓
PDCO
31.2
-0.22%↓
MDT
87.86
-1.21%↓
VEEV
221.66
-2.12%↓
A
109.71
-5.41%↓
HQY
82.88
-6.59%↓
PDCO
31.2
-0.22%↓
MDT
87.86
-1.21%↓
VEEV
221.66
-2.12%↓
A
109.71
-5.41%↓
HQY
82.88
-6.59%↓
PDCO
31.2
-0.22%↓
MDT
87.86
-1.21%↓
VEEV
221.66
-2.12%↓
A
109.71
-5.41%↓
HQY
82.88
-6.59%↓
PDCO
31.2
-0.22%↓
MDT
87.86
-1.21%↓
VEEV
221.66
-2.12%↓
A
109.71
-5.41%↓
HQY
82.88
-6.59%↓
PDCO
31.2
-0.22%↓
24h
Current
Min
Max
Income | -2.5M -36M |
---|---|
Sales | 8.3M 12M |
EPS | -0.69 |
Profit margin | -296.762 |
Employees | 59 |
EBITDA | 13M -17M |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +190.99% upside |
Next Earnings | 6 May 2025 |
---|
Market Cap | -7.3M 425M |
---|---|
Previous open | 0 |
Previous close | 0 |
Past performance is not a reliable indicator of future results.
27 Feb 2025, 15:29 UTC
Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million
DJ
Read
5 Aug 2024, 11:25 UTC
Zevra Shares Rally Premarket After FDA Panel Backs Arimoclomol
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 22.29 USD 190.99%
High 25 USD
Low 18 USD
Based on 8 Wall Street analysts offering 12 month price targets forKemPharm Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
8 ratings
8
Buy
0
Hold
0
Sell
Based on 8 analysts giving stock ratings to KemPharm Inc - Dist in the past 3 months.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$